产品资料

Tandutinib, Free Base **

如果您对该产品感兴趣的话,可以
产品名称: Tandutinib, Free Base **
产品型号: LC T-7802
产品展商: 原装进口
产品文档: 无相关文档

简单介绍

Tandutinib, Free Base **


Tandutinib, Free Base **  的详细介绍
Tandutinib, Free Base **

产品名称:Tandutinib, Free Base
产品货号:LC  T-7802
产品规格:1 G
Tandutinib (also known as MLN518 or CT53518) is an orally active inhibitor of Fms-like tyrosine kinase 3 (FLT3) kinase, PDGFRβ and c-Kit.  It inhibits FLT3 phosphorylation, downstream signaling and tumor growth in vitro and in animal models.  Cheng, Y. and Paz, K.  "Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications."  IDrugs 11:  46-56 (2008).
The sensitivity of cell lines to tandutinib is increased by FLT3 siRNA-induced down-regulation of FLT3.  Walters, D.K., et al.  "RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518."  Blood 105:  2952-2954 (2005).
In human FLT3-ITD-positive acute myelogenous leukemia (AML) cell lines, tandutinib induced apoptosis and inhibited FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways.  In Ba/F3 cells expressing different FLT3-ITD mutants, tandutinib also demonstrated inhibition of IL-3-independent cell growth and FLT3-ITD autophosphorylation, with an IC50 of 10-100 nM.  Tandutinib was a potent inhibitor of FLT3-ITD-induced disease in a murine model.  Kelly, L.M., et al.  "CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)."  Cancer Cell 1:  421-432 (2002).
Tandutinib inhibits the growth of blast colonies from FLT3 ITD-positive patients with acute myelocytic leukemia (AML) more effectively than for blast colonies from ITD-negative AML patients, at concentrations that do not significantly block colony formation of normal human progenitor cells.  Tandutinib has moderate toxicity toward normal hematopoiesis at concentrations that are used in treating FLT3 ITD-positive leukemia in mice.  Griswold, I.J., et al.  "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis."  Blood 104:  2912-2918 (2004).
Tandutinib inhibited FLT3 autophosphorylation and phosphorylation of STAT5 and ERK in FLT3-ITD-transformed Ba/F3 cells (IC50 = 500 nM).  However, there was a broad spectrum of sensitivity among the 8 activation loop mutants (IC50 = 500 nM - 10 µM) for the inhibition of phosphorylation of FLT3, STAT5, and ERK.  The relative cellular sensitivity of the mutants to tandutinib for proliferation of FLT3-transformed Ba/F3 cells correlated with IC50s in the biochemical assays, indicating that certain activation loop mutations in FLT3 confer resistance to tandutinib.  Clark, J.J., et al.  "Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518."  Blood 104:  2867-2872 (2004).
Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 25 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!
使用指南 付款方式 客户关怀 **与保密 法律帮助 服务条款 监察中心信箱
分享到:

沪公网安备 31011002002623号